在两个案例中,Belzutifan成功准了体质VHL变化的变化

Bicky Thapa1, Aditya Shreenivas1, Kathryn Bylow1

  • 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

概括

贝尔祖提凡是一种HIF-2α抑制剂,对具有VHL突变的晚期细胞癌 (RCC) 患者表现有前途. 两个不耐药的转移性RCC病例实现了长期的部分缓解,这表明有针对性治疗的潜力.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K